论文部分内容阅读
目的:探讨抗瘤增效方联合吉非替尼治疗老年非小细胞肺癌及对患者炎症因子,T细胞亚群水平及血清肿瘤标志物影响。方法:选取郑州大学附属肿瘤医院肿瘤内科非小细胞肺癌Ⅳ期老年患者84例,患者或家属签字同意,积极配合此次研究,按随机数字表法分组,对照组患者(42例)予以单纯吉非替尼治疗,研究组患者(42例)予以吉非替尼联合抗瘤增效方治疗,观察并记录所有患者治疗前后生存质量、炎症因子及T细胞亚群水平,同时对比临床疗效及不良反应状况。结果:对照组有效率低于研究组(P<0.05);与治疗前比较,两组患者治疗后生存质量、炎症因子及T细胞亚群水平均发生变化,研究组治疗后躯体功能,角色功能,社会功能,情绪功能评分高于对照组,研究组治疗后白细胞介素-2(interleukin-2,IL-2),白细胞介素-12(interleukin-12,IL-12)和γ-干扰素(interferon-γ,IFN-γ)水平高于对照组,研究组治疗后CD8+水平低于对照组,CD4+及CD4+/CD8+水平高于对照组(P<0.05);治疗后,对照组血管内皮生长因子(vascular endothelial growth factor,VEGF)升高,治疗组VEGF下降(P<0.05);与治疗前比较,两组患者癌胚抗原(carcinoembryonic antigen,CEA),糖抗原(carbohydrate antigen-125,CA125)及细胞角蛋白19片段21-1(cytokeratin 19 fragments,CYFRA21-1)差异无统计学意义,组间比较差异无统计学意义;两组患者不良反应较轻,无药物不良反应。结论:抗瘤增效方联合吉非替尼治疗老年非小细胞肺癌疗效确切,能提高生活质量及免疫功能。
Objective: To investigate the anti-tumor and side effects of gefitinib combined with gefitinib treatment of elderly patients with non-small cell lung cancer and inflammatory cytokines, T cell subsets and serum tumor markers. Methods: Eighty-four elderly patients with stage Ⅳ non-small cell lung cancer were enrolled in Department of Oncology, Affiliated Tumor Hospital, Zhengzhou University. Patients and their relatives signed the agreement and actively cooperated with the study. Patients in the control group (42 cases) The study group (n = 42) was given gefitinib combined with anti-tumor and synergistic treatment. The quality of life, inflammatory factors and T-cell subsets of all patients were observed and recorded before and after treatment. The clinical efficacy and adverse effects Reaction status. Results: The effective rate of the control group was lower than that of the study group (P <0.05). After treatment, the quality of life, inflammatory cytokines and T cell subsets of the two groups changed after treatment. The body function, , And social function and emotional function score were higher than those in the control group. After the treatment, the study group showed that interleukin-2 (IL-2), interleukin-12 (IL-12) and interferon- The level of CD8 + in the study group was lower than that in the control group, and the level of CD4 + and CD4 + / CD8 + in the study group was higher than that in the control group (P <0.05). After the treatment, the level of IFN-γ in the control group was significantly higher than that in the control group (P <0.05). Compared with pre-treatment, carcinoembryonic antigen (CEA), carbohydrate antigen-125 (CA125) And cytokeratin 19 fragments (CYFRA21-1) of cytokeratin 19 fragments had no statistical significance. There was no significant difference between the two groups. The patients in the two groups had less adverse reactions and no adverse drug reactions. Conclusion: The anti-tumor and side-effect combination gefitinib treatment of elderly non-small cell lung cancer curative effect is exact, can improve the quality of life and immune function.